Çilingir, B. Et Al. 2021. What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values. Eastern Journal of Medicine , vol.26, no.3 , 426-432.

Çilingir, B., Sünnetçioğlu, A., Yıldız, H., Erçek, B. M., & Baykal, N. D., (2021). What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values. Eastern Journal of Medicine , vol.26, no.3, 426-432.

Çilingir, Buket Et Al. "What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values," Eastern Journal of Medicine , vol.26, no.3, 426-432, 2021

Çilingir, Buket Et Al. "What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values." Eastern Journal of Medicine , vol.26, no.3, pp.426-432, 2021

Çilingir, B. Et Al. (2021) . "What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values." Eastern Journal of Medicine , vol.26, no.3, pp.426-432.

@article{article, author={Buket Mermit Et Al. }, title={What is the case of more accessibl e treatment options in COVID 19: Comparison of hydroxychloroquine and favipiravir based on laboratory values}, journal={Eastern Journal of Medicine}, year=2021, pages={426-432} }